Stereotaxis, Inc. Common Stock (NY:STXS)

1.180 UNCHANGED

Delayed Quote Updated: 8:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stereotaxis, Inc. Common Stock

< Previous 1 2 3 Next >

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript ↗

August 18, 2026

MAGiC catheter adoption accelerates with 12 U.S. sites now performing procedures.

Via The Motley Fool

Topics Earnings

Stereotaxis Q2 Earnings Call Highlights ↗

August 11, 2026

Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite...

Via MarketBeat

Topics Earnings

Unusual volume stocks in Monday's session ↗

July 20, 2026

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 16, 2026

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased...

Via Benzinga

Stereotaxis Inc (NYSEARCA:STXS) Slides 6% After Q1 Revenue Miss Despite Narrower-Than-Expected Loss ↗

May 12, 2026

Via Chartmill

STEREOTAXIS INC (NYSEARCA:STXS) Posts Narrower-Than-Expected Q4 Loss Despite Revenue Miss ↗

March 09, 2026

Via Chartmill

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

July 16, 2026

Via Chartmill

Stereotaxis Q1 Earnings Call Highlights ↗

May 15, 2026

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products...

Via MarketBeat

Topics Earnings

Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System

April 06, 2026

ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval...

Via MarketMinute

Topics Artificial Intelligence

Stereotaxis Earnings Preview ↗

November 08, 2024

Via Benzinga

Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"

April 06, 2026

ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that...

Via MarketMinute

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

3 Underrated Robotics Stocks Poised for Huge Gains ↗

December 15, 2025

Via MarketBeat

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 12, 2025

Via Benzinga

STEREOTAXIS INC (NYSEARCA:STXS) Stock Falls 9.5% After Q3 2025 Revenue Miss ↗

November 11, 2025

Stereotaxis stock fell sharply after Q3 2025 results, as a 13% revenue miss overshadowed a smaller-than-expected quarterly loss.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 11, 2025

Via Benzinga

A Look at Stereotaxis's Upcoming Earnings Report ↗

November 10, 2025

Via Benzinga

New Robotic System Promises Faster, Safer Care For Arrhythmia Patients ↗

September 22, 2025

Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions.

Via Benzinga

Earnings Scheduled For November 11, 2025 ↗

November 11, 2025

Via Benzinga

Stereotaxis Inc (NYSEARCA:STXS) Q2 2025 Earnings: Revenue Surpasses Forecasts, Losses Narrower Than Expected ↗

August 07, 2025

Stereotaxis Inc (NYSE:STXS) Q2 2025 earnings beat revenue estimates with $8.8M, narrowing losses to -$0.05 EPS. Stock rose 1.83% post-announcement.

Via Chartmill

Topics Earnings

What's Going On With Stereotaxis Shares Wednesday? ↗

March 19, 2025

Stereotaxis shares are moving higher on Wednesday after the company announced it was accepted into the NVIDIA Connect program.

Via Benzinga

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Earnings Scheduled For November 11, 2024 ↗

November 11, 2024

Via Benzinga

STXS Stock Earnings: Stereotaxis Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

STXS stock results show that Stereotaxis missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying ↗

June 18, 2024

Via Benzinga

STXS Stock Earnings: Stereotaxis Meets EPS, Misses Revenue for Q1 2024 ↗

May 13, 2024

STXS stock results show that Stereotaxis met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

3 Penny Stocks That Could Make a Big Comeback by the End of Q2 ↗

April 19, 2024

Although penny stocks to rebound represent one of the riskiest market categories, there could be some substance here.

Via InvestorPlace

7 Penny Stocks That Could 5X by the End of 2024 ↗

April 10, 2024

These seven penny stocks to buy have the potential to 5X your money by the end of 2024 if the right catalysts unfold.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.